Pediatrix Medical Group has acquired Georgia Perioperative Consultants, an anesthesia physician group practice that provides services to patients treated at facilities in the Atlanta metropolitan area.
Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals, have received marketing approval for Relistor subcutaneous injection from the European Commission.
Sound Surgical Technologies, a developer of the Vaser lipo system, has announced that all disposable products will be designed and manufactured in the US.
Mylan has announced that its subsidiary, Mylan Pharmaceuticals, has received tentative approval from the FDA for its abbreviated new drug application for Linezolid tablets, 600mg.
MED3OOO Group, a provider of healthcare management and technology products and services, has entered into a partnership arrangement with Mitsui & Co, a wholly owned subsidiary of Mitsui & Co, Ltd.
OncoGenex Technologies and Isis Pharmaceuticals have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011.
Movetis has announced that M0002 is progressing to Phase IIb following positive results of a Phase IIa multiple-dosing trial for the treatment of ascites.
Regenerx Biopharmaceuticals has completed enrollment and dosing of 40 healthy subjects for its Phase Ia clinical trial testing RGN-352, an injectable formulation of Tâ4 for potential use in treating acute myocardial infarction patients.
Cellectis has signed an agreement with Regeneron Pharmaceuticals, over the use of Cellectis's patents covering certain uses of homologous recombination for the generation of innovative human therapies, including the development of fully human monoclonal antibodies.
Senesco Technologies has contracted with VGXI to supply the plasmid portion of its combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.
Antigen Discovery has received a Phase II SBIR from the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources.
APP Pharmaceuticals has received final approvals from the FDA of its abbreviated new drug applications for Granisetron hydrochloride injection, 1mg/ml, 1ml single dose, and 1mg/ml, 4ml multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril injection.
Senesco Technologies has contracted with France-based Polyplus-transfection to supply Polyplus's 'in vivo-jetPEI' for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.
Bentley Pharmaceuticals has announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, Cpex
